Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,761.00
Bid: 1,757.50
Ask: 1,758.00
Change: 27.50 (1.59%)
Spread: 0.50 (0.028%)
Open: 1,736.00
High: 1,767.00
Low: 1,736.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Reform agenda puts China's economic superagency under scrutiny

Mon, 15th Jul 2013 21:02

By Alexandra Harney

SHANGHAI, July 16 (Reuters) - Behind China's twoinvestigations into irregular pricing of infant formula andpharmaceuticals announced this month is one powerful institutionand its struggle for relevance as Beijing attempts a transitionto a more consumption-led economy.

The investigations have entangled big foreign companiesincluding Danone SA, Nestle SA andGlaxoSmithKline Plc. But some analysts say there may besomething deeper at work - jockeying over the direction ofpolicy in the world's second largest economy in the years ahead.

The National Development and Reform Commission (NDRC),Beijing's economic superagency, sets policy for strategicindustries, approves big investments, mergers and acquisitions,and has the authority to influence prices for everything fromliquor to gasoline.

Its powers are so sweeping that it is often called the"little State Council".

But in recent months, as President Xi Jinping and Premier LiKeqiang have begun an attempt to steer China's economy away fromits reliance on state-led investment towards a moreconsumer-focused model, academics and even senior officials havebegun to publicly cast doubt on the NDRC's role.

While the NDRC has always had a price-setting role, itsdecision to launch high profile predatory pricing probes intoinfant formula and drugs now could be a bid by the commission toprove its usefulness as a regulator.

"On a fundamental level, the NDRC is scrambling to show thatit has something to contribute," says Barry Naughton, professorat the University of California, San Diego, and a specialist inChina's economy.

SHIFTING PRIORITIES

That the main economic policy body in the fastest-growingmajor economy over the past decade might feel the need to shoreup its position says much about the debate raging among Chinesepolicymakers. In key areas, the new leaders are trying to shiftChina's priorities in ways that represent a challenge to theNDRC's traditional dominance.

Evidence that dominance could be under threat includes thefact that Premier Li made the reduction of bureaucraticapprovals - one of the NDRC's main roles - a key plank of hisreform plan announced in March.

In May, Li also rejected a 40 trillion yuan ($6.5 trillion)urbanisation plan that the NDRC had proposed, sources familiarwith the matter told Reuters, although the commission deniesthis.

Xi and Li remain committed to urbanisation, but the push nowis "less about building stuff", says Arthur Kroeber, managingdirector of GaveKal Dragonomics Research, and more about helpingmigrants live "more fully-fledged urban lives".

Reducing bureaucratic red tape - such as the NDRC approvalsprocess - is another way the new administration would like toshrink the role of the state in the economy.

There are also concerns among academics about the NDRC as aninstitution. Founded in 1952 as the State Planning Commission,it is deeply rooted in China's command economy past, even as itcrafts policies for its mostly capitalist present.

Part of the debate is about whether, through its investmentapproval function, the NDRC is allocating resources asefficiently as possible, says Shi Lei, professor of economics atFudan University. Overcapacity plagues many industries in China.

With so much power concentrated in one institution,corruption is another worry - Liu Tienan, former NDRC vicechairman, is under investigation over allegations he took bribesto help a businessman defraud banks.

REGULATORY ROLE

The NDRC is no stranger to controversy. It has facedchallenges to its power before and has found ways to survive andeven increase its influence.

Indeed, this month's drugs and formula investigations couldwell be a sign that the NDRC is adapting to the new mood inBeijing by strengthening its role as a regulator.

Especially since the 2011 introduction of regulationsgoverning its role in implementing the 2008 Anti-Monopoly Law,the NDRC has been stepping up its investigations into pricingpractices.

In March, it imposed a 449 million yuan fine on two domesticliquor firms for setting minimum resale prices and a 10 millionyuan fine on eight real estate companies for misleadingcustomers and violating pricing regulations.

In January, it found six foreign LCD manufacturers guilty ofprice fixing and fined them 353 million yuan.

Few sectors pack the symbolic punch of infant formula, bothfor Chinese consumers and the government. Since 2008, whenmelamine in infant formula killed six babies and sickened300,000 others, the infant formula industry has epitomized thetrade-off between rapid economic growth and health and safety.

Driving down prices also supports Beijing's efforts to shiftthe economy away from a reliance on exports and investmenttoward a greater dependence on consumption. Drugs and infantformula are both commonly perceived as too expensive.

"Every time price reductions are made, it's mainly a publicrelations exercise," said Zhou Zhang, an analyst at ChinaMerchant Securities. "The NDRC trumpets how big reductions willbe, but when it comes down to it, prices only fall a bit. TheNDRC's main consideration is public relations."

The NDRC did not respond to a request for comment. Oneperson with knowledge of the NDRC investigations said that theywere being conducted at an unusually rapid pace.

The infant formula investigation also appears to cover notcollusion among companies, but how the retail prices for theseproducts are set - an issue where China's laws differ from thosein other countries, including the United States.

All of the infant formula companies targeted have reducedprices in China since the NDRC announced its investigation.

That might be good for consumers in the short term, butScott Kennedy, director of the Research Center for ChinesePolitics & Business at Indiana University, questioned the NDRC'scredentials as a consumer watchdog, given its central role inChina's export- and investment-led expansion of the past twodecades.

"This is an economy built by, for and of industry," he said.

More News
3 Apr 2024 22:01

Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs

WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.

Read more
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.